Let’s see how effective CRT is in Heart Failure
If you read the information below it is a real positive step towards the options now becoming available for the treatment of Heart Failure. Often patients feel as though Heart Failure meets a dead end but this is not always the case. Pumping Marvellous has a real focus around educating and giving options around what all the various treatments mean before they become an option. Forewarned is forearmed. It is also really very comforting to the millions that suffer with this condition see that great technical steps are being taken all the time from drug therapy with Serviers Ivabradine, Medtronics development in CRT and VAD’s (ventricular assist devices).
So familiarise yourself with CRT’s below. You don’t need to be an expert to understand their value.
Medtronic the US implantable device manufacturer announced the first patient enrollment in MIRACLE EF, which is a global clinical trial that will evaluate the effectiveness of cardiac resynchronization therapy-pacemakers (CRT) in delaying the progression of heart failure in symptomatic patients with mildly reduced heart pumping function. This large study will be the first to evaluate CRT in a widely under served patient group – those who have a slightly reduced left ventricular ejection fraction (LVEF) in the range of 36 to 50%, which means that their hearts work somewhat more efficiently than heart failure patients who are currently indicated for implanted device therapy because of their lower LVEF.
The CRT-P devices used in MIRACLE EF are not approved by the US FDA for the patient population being studied. Edward Schloss, M.D., FACC, performed the first implant at The Christ Hospital’s Lindner Research Center in Cincinnati; primary investigator for the site is Greg Egnaczyk, M.D., Ph.D., FACC.
“Previous studies have proven the real-world therapeutic benefits of CRT in treating mildly to severely symptomatic heart failure patients with moderately to severely reduced cardiac pumping capacity and electrical dyssynchrony,” said Professor Cecilia Linde, M.D., Ph.D., of Karolinska University Hospital in Stockholm, and worldwide principal investigator in the trial. “Through this large global study we hope to further our research on the overall effectiveness of CRT-P by showing its benefit in treating patients with mild-to-moderate heart failure symptoms, but with milder impairment of heart pumping capacity than previously studied.”
Approximately 275 centers throughout the world, in regions including the United States, Canada, Europe, Japan and developing markets, will enroll up to 2,300 patients in this double blind, randomized controlled trial. Patients will be followed for at least two years or until close of the study. Medtronic anticipates the trial will take four to five years to complete. The effectiveness of CRT-P in this patient population will be assessed using a composite endpoint of time to first event, defined as all-cause mortality or heart failure hospitalisation.